Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Long-Read Single-Cell RNA Sequencing Enables Cell Genotyping to Refine Subclone Detection in Chronic Lymphocytic Leukemia

ABSTRACT: Long-Read Single-Cell RNA Sequencing Enables Cell Genotyping to Refine Subclone Detection in Chronic Lymphocytic Leukemia

PROVIDER: PRJNA1080534 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Long-Read Single-Cell RNA Sequencing Enables Cell Genotyping to Refine Subclone Detection in Chronic Lymphocytic Leukemia

Project description:Bruton's tyrosine kinase (BTK) inhibitors are effective treatments for chronic lymphocytic leukemia (CLL) due to BTK’s role in B-cell survival and proliferation. Though effective, resistance occurs most commonly due to a BTKC481S mutation that inhibits drug binding. Here, we sought to understand the impact of co-occurring BTK resistance mutations with known CLL driver mutations and the differential transcriptomic behavior of BTK-resistant CLL subclones in six patients who acquired BTKC481S mutations. We utilize MAS-seq, a long-read scRNAseq technology, to increase transcript coverage and expand the set of mutations that can be used to link cells to tumor subclones.

2024-03-01 | GSE259253 | GEO

Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotypes and phenotypes in chronic lymphocytic leukemia.

Project description: Not available

| S-EPMC12047255 | biostudies-literature

Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia.

Project description: Not available

| S-EPMC10979946 | biostudies-literature

Genotyping of two patients with microdeletions of 16p11.2p12.2 to refine the breakpoint locations

Project description:Whole genome genoyping/copy-number analysis was performed on two patients with microdeletions of 16p11.2p12.2 to refine the breakpoint locations.

2007-09-01 | E-MEXP-1148 | biostudies-arrayexpress

Refine regulatory elements across the genome

Project description:Refine regulatory elements across the genome

| PRJNA627176 | ENA

Long-read structural variant discovery and targeted short read genotyping enables population scale characterization of structural variation in rhesus macaques.

Project description: Not available

| S-EPMC12636206 | biostudies-literature

Receptor kinase heterodimers refine cambium activity in Arabidopsis

Project description:Receptor kinase heterodimers refine cambium activity in Arabidopsis

| PRJNA1098741 | ENA

Transient Ddx61-enriched condensates refine heart regeneration programs

Project description:Transient Ddx61-enriched condensates refine heart regeneration programs

| PRJNA1033659 | ENA

A Genomic Approach to Improve Prognosis and Predict Therapeutic Response in Chronic Lymphocytic Leukemia (Duke_VA)

Project description:Chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy, characterized by a variable clinical course. While clinical and laboratory parameters are increasingly being used to refine prognosis, they do not accurately predict response to commonly used therapy. We used gene expression profiling to generate and further refine prognostic and predictive markers. Genomic signatures that reflect progressive disease and responses to chemotherapy or chemo-immunotherapy were created using cancer cell lines and patient leukemia samples. We validated these signatures using independent clinical data from four separate cohorts representing a total of 301 CLL patients. A prognostic genomic signature created from patient leukemic cell gene expression data coupled with clinical parameters could statistically differentiate patients with stable or progressive disease in the training dataset. The progression signature was then validated in two independent datasets, demonstrating a capacity to accurately identify patients at risk for progressive disease. In addition, two distinct genomic signatures that predict response to chlorambucil or pentostatin, cyclophosphamide, and rituximab were also generated and were shown to accurately distinguish responding and non-responding CLL patients. Microarray analysis of CLL patients’ lymphocytes can be used to refine prognosis and predict response to different therapies. These results have direct implications for standard and investigational therapeutics in CLL patients. Keywords: Gene Expression Profiling of two phenotypic states

2009-10-31 | GSE10138 | GEO

Mus musculus strain:MC3T3-E1 Subclone 4

Project description:Mus musculus strain:MC3T3-E1 Subclone 4 Transcriptome or Gene expression

| PRJNA233971 | ENA